Definium Therapeutics says Phase 3 Panorama trial meets primary endpoint for DT120 ODT in generalized anxiety disorder

DFTX•2026-09-14

Phase 3 Panorama trial results

Definium Therapeutics reported positive topline Phase 3 Panorama results for DT120 ODT in generalized anxiety disorder; results were released now.

The trial met the main goal and all key secondary goals, showing clinically meaningful improvement versus placebo with rapid, sustained benefit.
DT120 ODT was generally well tolerated, with no new safety concerns flagged in the study.
A pre-NDA meeting is scheduled for 4Q 2026; NDA filing is anticipated in 1H 2027.

Definium Therapeutics says Phase 3 Panorama trial meets primary endpoint for DT120 ODT in generalized anxiety disorder

Phase 3 Panorama trial results

Related News

Euro zone bond yields climb as oil prices rise; central banks in focus

TAT Technologies partners with Beyond Aero on thermal management architecture for hydrogen-electric business jet

Scholar Rock Holding Corporation <SRRK.O>: Truist Securities raises target price to $76 from $55

TRX Gold posts record Q4 output of 8,173 oz, hits top end of FY2026 guidance at 29,650 oz

Hain Celestial Q4 sales miss estimates on divestiture impact